Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt.

NCT00817206 is registered in ClinicalTrials.gov with Veloxis Pharmaceuticals as lead sponsor.

NCT NCT00817206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00817206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt.
Lead sponsor
Veloxis Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2008
Completion date
February 28, 2011
Enrollment
326 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal failure